Partners In Investing

After a painful 2022, the opportunity set is far better than it was a year ago. For the first time in several years, certain assets and strategies are either outright cheap or at least fair value.

The first leg of the bubble bursting is complete. Now it gets more complicated. A further correction is highly likely, but the timing and extent of the next leg down are uncertain.

In this webcast, we review the 2022 investment landscape and its impact on GMO Asset Allocation portfolios. We then show how the 2022 downturn informs our Asset Allocation views going forward. Importantly, we highlight the biggest...

We believe the most attractive group of U.S. stocks today is one that is likely absent from most existing portfolios, or at least woefully underrepresented – the cheapest quintile or “Deep” Value.

In the webcast, Ben Inker, Michelle Morphew, and Catherine LeGraw cover forecasts for Value outperformance, compelling dislocations in U.S. Deep Value and Value/Growth spreads globally, and strategies for capturing the opportunity...

In this paper, we discuss the recent integration of ESG as a systematic risk factor in GMO’s EM corporate debt investment process.

Value, especially U.S. Deep Value, remains attractive and is positioned to win – even if it remains cheap.

The quarter started well, but by the end of September had proved to be another ugly quarter for traditional investments. Read the Asset Allocation team’s third quarter market review and outlook.